Anti-aging combination peptide and its application

Abstract

The present invention provides an anti-aging combination peptide and its application, which is composed of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8, and 0.5-5% hexapeptide-9. Since hexapeptide-9 is added to the original three polypeptides of palmitoyl tripeptide-5, palmitoyl pentapeptide-4, and acetyl hexapeptide-8, and a suitable ratio is adopted, this combination can significantly promote the expression of collagen I, collagen III, and collagen IV genes, significantly improve the effect of the combination peptide in increasing collagen content, provide a theoretical basis for the production of collagen in the skin, and can also inhibit the secretion of acetylcholine and reduce the generation of dynamic lines, thereby having a better anti-aging and wrinkle-removing effect on the skin.

Description

Technical Field

[0001] The present invention relates to the field of cosmetic technology, and more specifically, to an anti-aging combination peptide and its application, in particular to an anti-aging combination peptide with a suitable ratio and its application in effectively promoting the expression of Collagen I, Collagen III and Collagen IV genes and inhibiting acetylcholine secretion. Background Art

[0002] As we age, the skin's morphology, structure, and physiological functions change. Skin aging is influenced by multiple factors, including light exposure, staying up late, and smoking. Healthy skin should be smooth, moisturized, and elastic. Free radicals damage collagen and active substances within normal cells, forming fine lines and wrinkles. Dry lines form when the skin loses its elasticity due to evaporation and dehydration.

[0003] Anti-wrinkle and anti-aging peptides can regulate muscle contraction by modulating the release of neurotransmitters, thereby eliminating wrinkles. Alternatively, they can boost collagen and elastin synthesis, improving skin elasticity and firmness and improving static wrinkles, thereby combating aging. However, using a single peptide has a relatively simple anti-aging mechanism, and simply stacking concentrations may not necessarily deliver the desired boost. Therefore, how to synergistically enhance the anti-wrinkle and anti-aging effects of peptides has become a hot topic among researchers.

[0004] Acetyl Hexapeptide-8 is a neurotransmitter inhibitory peptide that competes for synaptosomal-associated protein 25 (SNAP-25) at the site of the thiovesicle complex, thereby affecting the formation of the complex and preventing the vesicles from effectively releasing the neurotransmitter acetylcholine, thereby weakening muscle contraction and preventing the formation of wrinkles. It can significantly eliminate dynamic lines such as crow's feet, forehead wrinkles, and nasolabial folds.

[0005] Palmitoyl Pentapeptide-4 can stimulate the synthesis of collagen and glycosaminoglycans (GAGs), increase skin thickness, and thus effectively reverse aging and reduce wrinkles.

[0006] Palmitoyl Tripeptide-5 activates transforming growth factor-β (TGF-β), stimulates fibroblast division and proliferation, strongly promotes collagen production, replenishes extracellular matrix proteins, strengthens connective tissue, and inhibits the activity of matrix metalloproteinases to prevent collagen decomposition, thereby making the skin elastic and effectively removing wrinkles.

[0007] Therefore, the inventors initially hoped to use a combination of three peptides: acetyl hexapeptide-8, palmitoyl pentapeptide-4, and palmitoyl tripeptide-5 to prepare a skin care product. However, research has shown that simply combining these three peptides does not achieve a good synergistic anti-wrinkle and anti-aging effect. Therefore, there is an urgent need to find a peptide combination that can truly achieve synergistic anti-wrinkle and anti-aging effects. Summary of the Invention

[0008] To solve the above problems, the present invention provides an anti-aging combination peptide, which is composed of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9, calculated by weight percentage. This combination, because hexapeptide-9 is added to the original three polypeptides of palmitoyl tripeptide-5, palmitoyl pentapeptide-4 and acetyl hexapeptide-8, and a suitable proportion is adopted, can significantly promote the expression of collagen I, collagen III and collagen IV genes, significantly improve the effect of the combination peptide in increasing collagen content, provide a theoretical basis for the production of collagen in the skin, and at the same time inhibit the secretion of acetylcholine and reduce the generation of dynamic lines, thereby being able to play a better anti-aging and wrinkle-removing effect on the skin.

[0009] In one aspect, the present invention provides an anti-aging composition, comprising palmitoyl tripeptide-5, palmitoyl pentapeptide-4, acetyl hexapeptide-8, and hexapeptide-9.

[0010] The inventors initially hoped to use acetyl hexapeptide-8, palmitoyl pentapeptide-4, and palmitoyl tripeptide-5 to prepare a composition for anti-aging skin care products. However, a large number of studies have shown that no matter how the ratio is optimized, it is difficult to obtain a satisfactory synergistic anti-wrinkle and anti-aging effect by using a simple combination of these three polypeptides. The effect of this combination on promoting the expression of collagen I, collagen III, and collagen IV genes is not very ideal, especially in promoting the expression of collagen I and collagen III genes.

[0011] The inventors then further optimized the types and proportions of peptides and discovered that a peptide combination prepared by combining hexapeptide-9 with acetyl hexapeptide-8, palmitoyl pentapeptide-4, and palmitoyl tripeptide-5 significantly enhanced the expression of collagen I, collagen III, and collagen IV genes, with a significant synergistic effect. The combination also inhibited acetylcholine secretion, creating a novel peptide composition with significant synergistic effects in enhancing skin activity. This peptide composition combines peptides with different mechanisms of action, exerting their effects at different targets, thereby achieving a better synergistic effect.

[0012] Furthermore, the composition consists of 0.1-1% of palmitoyl tripeptide-5, 0.5-5% of palmitoyl pentapeptide-4, 1-10% of acetyl hexapeptide-8 and 0.5-5% of hexapeptide-9.

[0013] The anti-aging polypeptide composition provided by the present invention is a composition prepared in an appropriate ratio. That is to say, only within the ratio range provided by the present invention can a significant synergistic effect be achieved, while at other ratios, it may be difficult to obtain the ideal effect.

[0014] Furthermore, the composition consists of 0.2% palmitoyl tripeptide-5, 1% palmitoyl pentapeptide-4, 2% acetyl hexapeptide-8 and 1% hexapeptide-9.

[0015] Studies have shown that when the composition consists of 0.2% palmitoyl tripeptide-5, 1% palmitoyl pentapeptide-4, 2% acetyl hexapeptide-8 and 1% hexapeptide-9, the synergistic effect of promoting the expression of collagen I, collagen III and collagen IV genes is most significant. Therefore, the composition at this ratio is a golden ratio composition.

[0016] On the other hand, the present invention provides a use of a composition for preparing an anti-aging preparation, wherein the composition consists of palmitoyl tripeptide-5, palmitoyl pentapeptide-4, acetyl hexapeptide-8 and hexapeptide-9.

[0017] Furthermore, the composition achieves anti-aging by promoting the expression of one or more genes among Collagen I, Collagen III and Collagen IV, or achieves anti-aging by inhibiting the secretion of acetylcholine.

[0018] Acetylcholine is a neurotransmitter that can specifically act on various cholinergic receptors and can also promote the formation of expression lines (dynamic lines). By inhibiting the secretion of acetylcholine, the formation of dynamic lines can be reduced, thereby helping to improve the anti-aging effect.

[0019] Furthermore, the composition consists of 0.1-1% of palmitoyl tripeptide-5, 0.5-5% of palmitoyl pentapeptide-4, 1-10% of acetyl hexapeptide-8 and 0.5-5% of hexapeptide-9.

[0020] On the other hand, the present invention provides a composition for preparing a preparation for simultaneously promoting the expression of one or more genes in Collagen I, Collagen III and Collagen IV, wherein the composition is composed of palmitoyl tripeptide-5, palmitoyl pentapeptide-4, acetyl hexapeptide-8 and hexapeptide-9.

[0021] Furthermore, the composition consists of 0.1-1% of palmitoyl tripeptide-5, 0.5-5% of palmitoyl pentapeptide-4, 1-10% of acetyl hexapeptide-8 and 0.5-5% of hexapeptide-9.

[0022] On the other hand, the present invention provides a composition for preparing a preparation for promoting the expression of Collagen I gene, wherein the composition is composed of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9.

[0023] On the other hand, the present invention provides a composition for preparing a preparation for promoting Collagen III gene expression, wherein the composition is composed of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9.

[0024] On the other hand, the present invention provides a composition for preparing a preparation for promoting Collagen IV gene expression, wherein the composition is composed of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9.

[0025] On the other hand, the present invention provides a composition for preparing a preparation for inhibiting acetylcholine secretion, wherein the composition is composed of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9.

[0026] On the other hand, the present invention provides the use of hexapeptide-9 for preparing a preparation for improving the effect of a composition in promoting the expression of one or more genes in Collagen I, Collagen III or Collagen IV, wherein the composition is composed of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9.

[0027] On the other hand, the present invention provides the use of hexapeptide-9 for preparing a preparation for improving the effect of a composition in inhibiting acetylcholine secretion, wherein the composition is composed of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9.

[0028] The composition provided by the present invention can be used to prepare skin care products with anti-aging effects. Within the scope that does not impair the effects of the present invention, various ingredients commonly used in the fields of cosmetics and quasi-drugs can be appropriately formulated as needed, such as powder components, moisturizers, emulsifiers, thickeners, metal ion sequestering agents, pigments, pH adjusters, skin nutrients, vitamins, preservatives, antioxidants, antioxidant adjuvants, fragrances, etc.

[0029] In addition, the polypeptide composition provided by the present invention can also be prepared in the form of a lyophilized powder, which can greatly improve the stability of the polypeptide during storage and use, and still maintain a high degree of activity during use, thereby exerting its maximum efficacy.

[0030] In summary, the beneficial effects of the present invention are:

[0031] 1. Provided is an anti-aging composition consisting of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8, and 0.5-5% hexapeptide-9;

[0032] 2. The use of this combination can significantly promote the expression of collagen I, collagen III and collagen IV genes, significantly improving the effect of the combined peptide in increasing collagen content, providing a theoretical basis for the production of collagen in the skin. At the same time, it can also inhibit the secretion of acetylcholine and reduce the formation of dynamic lines, thereby having a better anti-aging and wrinkle-removing effect on the skin;

[0033] 3. Provided is a golden ratio composition consisting of 0.2% palmitoyl tripeptide-5, 1% palmitoyl pentapeptide-4, 2% acetyl hexapeptide-8 and 1% hexapeptide-9, which has better effects on promoting the expression of collagen I, collagen III and collagen IV genes and inhibiting the secretion of acetylcholine. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is a schematic diagram showing the effects of different sample groups on promoting the expression of Collagen I in Example 1;

[0035] Figure 2 This is a schematic diagram showing the effects of different sample groups on promoting the expression of Collagen III in Example 1;

[0036] Figure 3 This is a schematic diagram showing the effects of different sample groups on promoting Collagen IV expression in Example 1;

[0037] Figure 4 Schematic diagram of the effects of different sample groups on inhibiting acetylcholine secretion in Example 2. DETAILED DESCRIPTION

[0038] The present invention will be further described in detail below with reference to the examples. It should be noted that the examples described below are intended to facilitate understanding of the present invention and do not have any limiting effect on the present invention.

[0039] Example 1 Effects of Peptide Compositions with Different Combinations and Ratios on Promoting the Expression of Collagen I, Collagen III, and Collagen IV

[0040] 1. Test materials

[0041] Test system: The cells used in this test are fibroblasts, batch number: Fb19052002, provided by Guangdong Boxi Biotechnology Co., Ltd.

[0042] Main reagents: low-glucose DMEM medium (Boxi Biotechnology), PBS (Boster), TGF-β1 (Peprotech), RNAiso Plus (Takara), reverse transcription kit (Takara), fluorescent dye (Takara).

[0043] Main equipment: CO2 incubator (Thermo, 150I), clean bench (Suzhou Antai, SW-CJ-1F), microplate reader (BioTek, Epoch), fluorescence quantitative PCR instrument (BioRad, CFX-96).

[0044] 2. Test methods

[0045] According to the test plan (Table 1), the working solutions of the test substances of sample groups A, B, C, D, and E were prepared respectively, with three replicates for each sample group.

[0046] Table 1. Test plan

[0047]

[0048] Then, according to the following steps, the test substance working solutions of sample groups A, B, C, D, and E were added to the fibroblasts respectively and fluorescence quantitative PCR detection was performed:

[0049] 1) Inoculation: 2×10 5 The cells were seeded into 6-well plates at a seeding density of 100 cells / well and incubated overnight in an incubator (37° C., 5% CO 2 ).

[0050] 2) Dosing: According to the test scheme in Table 1, when the cell plating rate in the 6-well plate reaches 40% to 60%, group dosing is carried out, with a dosage of 2 mL per well, 3 replicate wells per group, and incubation in an incubator (37°C, 5% CO2) for 24 h.

[0051] 3) Genetic detection: After 24 hours of culture, the supernatant was discarded, and the cells were washed twice with 1 mL / well PBS. 1 mL RNAisoPlus was added to each well, and the cells were lysed by pipetting. The samples were collected. RNA was extracted, reverse transcribed to cDNA, and fluorescent quantitative PCR was performed. -△△CT Method to calculate the results.

[0052] 3. Data processing and analysis

[0053] GraphPad Prism was used for plotting, and the results are expressed as Mean ± SD. The t-test was used for statistical analysis between the groups. All statistical analyses were two-tailed. P < 0.05 was considered to indicate a significant difference, and P < 0.01 was considered to indicate a very significant difference. Figures 1 to 3 As shown, Figure 1 Schematic diagram of the effects of different sample groups on promoting the expression of Collagen I; Figure 2 Schematic diagram of the effects of different sample groups on promoting the expression of Collagen III; Figure 3 Schematic diagram of the effects of different sample groups on promoting Collagen IV expression.

[0054] Depend on Figure 1 It can be seen that when acetyl hexapeptide-8, palmitoyl tripeptide-5, and palmitoyl pentapeptide-4 are used in combination, such as sample group A and sample group C, the amplification factor for promoting the expression of Collagen 1 is about 1.1 or 1.2. It can be seen that when the three peptides are combined, no matter what ratio is adopted, it is difficult to obtain a satisfactory effect of promoting the expression of Collagen 1; when hexapeptide-9 is used alone, such as sample group E, the amplification factor for promoting the expression of Collagen 1 can only reach 1.1, which is difficult to achieve a satisfactory effect of promoting the expression of Collagen 1; when acetyl hexapeptide-8, palmitoyl tripeptide-5, palmitoyl pentapeptide-4 and hexapeptide-9 are used, according to the ratio of sample group B (the ratio of the three peptides is consistent with A), the amplification factor for promoting the expression of Collagen 1 can be increased to 1.5, and the result has a very significant difference, which is an effect that is currently difficult to achieve in other formulas. It can be seen that adding hexapeptide-9 on the basis of sample group A can play a very significant synergistic role, significantly improving the effect of promoting Collagen 1. The results show that the ratio of sample group D is less effective in promoting the expression of Collagen I, and it is difficult to achieve a synergistic effect. This shows that the combination of the four polypeptides provided by sample group B is a golden ratio combination. The four polypeptide compositions at this ratio can truly achieve a satisfactory effect in promoting the expression of Collagen I and can demonstrate a better synergistic effect.

[0055] Depend on Figure 2It can be seen that when the three peptides of acetyl hexapeptide-8, palmitoyl tripeptide-5 and palmitoyl pentapeptide-4 are used in combination, the amplification factor of sample group A in promoting the expression of Collagen III is 1.1, and the amplification factor of sample group C in promoting the expression of Collagen III is 1.6. It can be seen that when the three peptides are combined, the effect of promoting the expression of Collagen III is poor when the proportion relationship of sample group A is adopted, and the effect of promoting the expression of Collagen III is improved when the proportion relationship of sample group C is adopted; when sample group E uses hexapeptide-9 alone, the amplification factor of promoting the expression of Collagen III can only reach 1.1, which is difficult to achieve satisfactory promotion of Collagen III. When acetyl hexapeptide-8, palmitoyl tripeptide-5, palmitoyl pentapeptide-4 and hexapeptide-9 are used, according to the ratio of sample group B (the ratio of the three peptides is consistent with A), the amplification factor of promoting the expression of Collagen III can reach nearly 1.94, and the result has a very significant difference. It can be seen that adding hexapeptide-9 on the basis of sample group A can play a very significant synergistic effect and significantly improve the effect of promoting the expression of Collagen III; when the ratio of sample group D is adopted, the effect of promoting the expression of Collagen III is significantly reduced to 1.3, and it is difficult to play a synergistic effect. It can be seen that the combination of the four polypeptides provided by sample group B is a golden ratio combination. The four polypeptide compositions under this ratio can truly obtain a satisfactory effect of promoting the expression of Collagen III, reflecting a better synergistic effect.

[0056] Depend on Figure 3It can be seen that when acetyl hexapeptide-8, palmitoyl tripeptide-5, and palmitoyl pentapeptide-4 are used in combination, such as sample group A and sample group C, the amplification factor for promoting the expression of Collagen I is about 1.7. It can be seen that when the three peptides are combined, no matter what ratio is adopted, it is difficult to obtain a satisfactory effect of promoting the expression of Collagen IV; when sample group E uses hexapeptide-9 alone, the amplification factor for promoting the expression of Collagen III can only reach 1.75, which is difficult to achieve a satisfactory effect of promoting the expression of Collagen IV; when acetyl hexapeptide-8, palmitoyl tripeptide-5, palmitoyl pentapeptide-4 and hexapeptide-9 are used, according to the ratio of sample group B (the ratio of the three peptides is consistent with A), the amplification factor for promoting the expression of Collagen IV can reach 2.17, and the result has a very significant difference. It can be seen that adding hexapeptide-9 on the basis of sample group A can play a very significant synergistic role and significantly enhance the effect of promoting the expression of Collagen IV; and when the ratio of sample group D is adopted, it promotes Collagen IV. The effect of promoting Collagen IV expression decreased significantly, falling to 1.4, making it difficult to achieve a synergistic effect. This shows that the combination of the four polypeptides provided by Sample Group B is a suitable ratio combination. The four polypeptide combinations at this ratio can achieve a satisfactory effect of promoting Collagen IV expression and can demonstrate a better synergistic effect.

[0057] It can also be seen that in the composition of palmitoyl tripeptide-5, palmitoyl pentapeptide-4, acetyl hexapeptide-8 and hexapeptide-9, when an appropriate amount of hexapeptide-9 is added, a significant synergistic effect is achieved. However, when the hexapeptide-9 content is high and the palmitoyl pentapeptide-4 content is low, a good synergistic effect cannot be achieved. Therefore, when the golden ratio combination provided by sample group B is used, 2% acetyl hexapeptide-8, 0.2% palmitoyl tripeptide-5, 1% palmitoyl pentapeptide-4, and 1% hexapeptide-9 are used for formulation, a significant synergistic effect can be achieved.

[0058] In addition, this embodiment experiments on a composition of palmitoyl tripeptide-5, palmitoyl pentapeptide-4, acetyl hexapeptide-8 and hexapeptide-9 within a certain proportion range. The study shows that a composition of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9 can achieve satisfactory effects in promoting the expression of Collagen I, Collagen III and Collagen IV, and can exhibit better synergistic effects. However, the best effect is a composition of 2% acetyl hexapeptide-8, 0.2% palmitoyl tripeptide-5, 1% palmitoyl pentapeptide-4 and 1% hexapeptide-9. It can be seen that a composition of 2% acetyl hexapeptide-8, 0.2% palmitoyl tripeptide-5, 1% palmitoyl pentapeptide-4 and 1% hexapeptide-9 is a golden ratio composition.

[0059] Example 2 Effect of the anti-aging composition on acetylcholine content

[0060] 1. Test materials

[0061] Test system: The cells used in this test are neuronal cells, provided by Guangdong Boxi Biotechnology Co., Ltd.

[0062] Main reagents: high glucose DMEM medium (Boxi Biotechnology), fetal bovine serum (Lanzhou Rongye), PBS (Boster), acetylcholine kit (Nanjing Jiancheng).

[0063] Main equipment: CO2 incubator (Thermo, 150I), clean bench (Suzhou Antai, SW-CJ-1F), microplate reader (BioTek, Epoch).

[0064] 2. Test methods

[0065] Working solution preparation: Prepare the working solution of the test substance according to the test scheme in Table 2, with three replicates for each sample group.

[0066] Table 2. Test plan

[0067]

[0068] Steps:

[0069] 1) Seeding: Cells were seeded into 6-well plates at a seeding density of 2×10 5 cells / well and incubated overnight in an incubator (37° C., 5% CO 2 ).

[0070] 2) Dosing: According to the test scheme in Table 2, when the cell plating rate in the 6-well plate reaches 40% to 60%, group dosing is carried out, with a dosage of 2 mL per well, 3 replicate wells per group, and incubation in an incubator (37°C, 5% CO2) for 24 h.

[0071] 3) Kit detection: Collect the cell culture supernatant and detect the acetylcholine content by ELISA according to the instructions of the detection kit.

[0072] 3. Data processing and analysis

[0073] GraphPad Prism was used for plotting, and the results are expressed as Mean ± SD. The t-test was used for statistical analysis between the groups. All statistical analyses were two-tailed. P < 0.05 was considered to indicate a significant difference, and P < 0.01 was considered to indicate a very significant difference. Figure 4 shown.

[0074] Depend on Figure 4 It can be seen that compared with the blank control, when sample groups A and C used a combination of acetyl hexapeptide-8, palmitoyl tripeptide-5, and palmitoyl pentapeptide-4 peptides, the acetylcholine content was reduced to 25-27 μg / mL, which can inhibit the secretion of acetylcholine to a certain extent; when sample D was used, a single hexapeptide-9 could not inhibit the secretion of acetylcholine, and the acetylcholine content was 35 μg / mL; when sample group B was used (equivalent to adding 1% hexapeptide-9 to sample group A), it could have a significant synergistic effect on inhibiting the secretion of acetylcholine; but when sample group D was used, it was difficult to reflect the effect of inhibiting the secretion of acetylcholine.

[0075] It can be seen that when the composition provided by sample group B is formulated with 2% acetyl hexapeptide-8, 0.2% palmitoyl tripeptide-5, 1% palmitoyl pentapeptide-4, and 1% hexapeptide-9, it can exert a significant synergistic effect on inhibiting acetylcholine.

[0076] In addition, this example experiments on a composition of palmitoyl tripeptide-5, palmitoyl pentapeptide-4, acetyl hexapeptide-8 and hexapeptide-9 within a certain proportion range. The study shows that a composition of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9 can all exert a significant synergistic effect on inhibiting acetylcholine, but the best effect is the composition of 2% acetyl hexapeptide-8, 0.2% palmitoyl tripeptide-5, 1% palmitoyl pentapeptide-4, and 1% hexapeptide-9. It can be seen that the composition of 2% acetyl hexapeptide-8, 0.2% palmitoyl tripeptide-5, 1% palmitoyl pentapeptide-4, and 1% hexapeptide-9 is a golden ratio composition.

[0077] Although the present invention is disclosed as above, the present invention is not limited thereto. Any person skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the scope defined by the claims.

Claims

1. A composition for preparing an anti-aging preparation for promoting the expression of Collagen I, Collagen III, and Collagen IV genes, characterized in that: The active ingredients of the composition are composed of 0.1-1% of palmitoyl tripeptide-5, 0.5-5% of palmitoyl pentapeptide-4, 1-10% of acetyl hexapeptide-8 and 0.5-5% of hexapeptide-9 by weight of the composition.

2. A composition for preparing an anti-aging preparation for inhibiting acetylcholine secretion, characterized in that: The active ingredients of the composition are composed of 0.1-1% of palmitoyl tripeptide-5, 0.5-5% of palmitoyl pentapeptide-4, 1-10% of acetyl hexapeptide-8 and 0.5-5% of hexapeptide-9 by weight of the composition.

3. The anti-aging composition for use according to claim 1 or 2, characterized in that: The active ingredients of the composition are composed of 0.1-1% palmitoyl tripeptide-5, 0.5-5% palmitoyl pentapeptide-4, 1-10% acetyl hexapeptide-8 and 0.5-5% hexapeptide-9 in percentages by weight of the composition.

Images